PubMed

Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group.

[No authors listed]

Ann Intern Med. 1996 Jan 15;124(2):212-22.PMID: 8533996 [PubMed - indexed for MEDLINE]Related articlesFree article

Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group.

Browman GP, Bergsagel D, Sicheri D, O'Reilly S, Wilson KS, Rubin S, Belch A, Shustik C, Barr R, Walker I, et al.

J Clin Oncol. 1995 Sep;13(9):2354-60.PMID: 7666094 [PubMed - indexed for MEDLINE]Related articles

Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. Cooperative Study Group.

Westin J, Rödjer S, Turesson I, Cortelezzi A, Hjorth M, Zador G.

Br J Haematol. 1995 Mar;89(3):561-8.PMID: 7734355 [PubMed - indexed for MEDLINE]Related articles

Interferon therapy during the plateau phase of multiple myeloma: an update of a Swedish multicenter study.

Westin J.

Semin Oncol. 1991 Oct;18(5 Suppl 7):37-40.PMID: 1948128 [PubMed - indexed for MEDLINE]Related articles

Interferon-alpha-2b with VMCP for induction in multiple myeloma: the Israel Myeloma Cooperative Group experience.

Cohen AM, Meytes D, Many A, Brenner B, Aghai E, Shaklai M, Kaufman S, Shtalrid M, Attias D, Manor Y, et al.

Isr J Med Sci. 1995 Oct;31(10):604-10.PMID: 7591683 [PubMed - indexed for MEDLINE]Related articles

Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon-alpha with melphalan and prednisone (MP) and interferon-alpha (IFN-alpha) in patients with good-prognosis multiple myeloma: a prospective randomized study. Greek Myeloma Study Group.

Zervas K, Pouli A, Gregoraki B, Anagnostopoulos N, Dimopoulos MA, Bourantas K, Tzilianos M, Barbarousi D, Venetis E, Vyniou N, Maniatis A.

Eur J Haematol. 2001 Jan;66(1):18-23.PMID: 11168503 [PubMed - indexed for MEDLINE]Related articles

A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study.

Cooper MR, Dear K, McIntyre OR, Ozer H, Ellerton J, Canellos G, Bernhardt B, Duggan D, Faragher D, Schiffer C.

J Clin Oncol. 1993 Jan;11(1):155-60.PMID: 8418228 [PubMed - indexed for MEDLINE]Related articles

Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.

Salmon SE, Crowley JJ, Grogan TM, Finley P, Pugh RP, Barlogie B.

J Clin Oncol. 1994 Nov;12(11):2405-14.PMID: 7964957 [PubMed - indexed for MEDLINE]Related articles

Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.

Oken MM, Harrington DP, Abramson N, Kyle RA, Knospe W, Glick JH.

Cancer. 1997 Apr 15;79(8):1561-7.PMID: 9118039 [PubMed - indexed for MEDLINE]Related articlesFree article

Maintenance treatment with interferon alpha-2b in multiple myeloma: a prospective randomized study from PETHEMA (Program for the Study and Treatment of Hematological Malignancies, Spanish Society of Hematology).

Bladé J, San Miguel JF, Escudero ML, Fontanillas M, Besalduch J, Gardella S, Arias J, García-Conde J, Carnero M, Marti JM, Rozman C, Estapé J, Montserrat E.

Leukemia. 1998 Jul;12(7):1144-8.PMID: 9665202 [PubMed - indexed for MEDLINE]Related articles

The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.

Oken MM, Leong T, Lenhard RE Jr, Greipp PR, Kay NE, Van Ness B, Keimowitz RM, Kyle RA.

Cancer. 1999 Sep 15;86(6):957-68.PMID: 10491521 [PubMed - indexed for MEDLINE]Related articlesFree article

Interferon alfa-2b with VMCP compared to VMCP alone for induction and interferon alfa-2b compared to controls for remission maintenance in multiple myeloma: interim results.

Ludwig H, Cohen AM, Huber H, Nachbaur D, Jungi WF, Senn H, Günczler P, Schüller J, Eckhardt S, Seewann HL, et al.

Eur J Cancer. 1991;27 Suppl 4:S40-5.PMID: 1799476 [PubMed - indexed for MEDLINE]Related articles

Interferon therapy during the plateau phase of multiple myeloma: an update of the Swedish study.

Westin J, Cortelezzi A, Hjorth M, Rödjer S, Turesson I, Zador G.

Eur J Cancer. 1991;27 Suppl 4:S45-8.PMID: 1799477 [PubMed - indexed for MEDLINE]Related articles

Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group.

Wisløff F, Hjorth M, Kaasa S, Westin J.

Br J Haematol. 1996 Aug;94(2):324-32.PMID: 8759893 [PubMed - indexed for MEDLINE]Related articles

Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma.

Oken MM, Kyle RA, Greipp PR, Kay NE, Tsiatis A, Gregory SA, Spiegel R J, O'Connell M J.

Leuk Lymphoma. 1996 Feb;20(5-6):447-52.PMID: 8833401 [PubMed - indexed for MEDLINE]Related articles

Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO).

Pönisch W, Mitrou PS, Merkle K, Herold M, Assmann M, Wilhelm G, Dachselt K, Richter P, Schirmer V, Schulze A, Subert R, Harksel B, Grobe N, Stelzer E, Schulze M, Bittrich A, Freund M, Pasold R, Friedrich T, Helbig W, Niederwieser D; East German Study Group of Hematology and Oncology (OSHO).

J Cancer Res Clin Oncol. 2006 Apr;132(4):205-12. Epub 2006 Jan 10.PMID: 16402269 [PubMed - indexed for MEDLINE]Related articles

Interferon alfa-2b/melphalan/prednisone in previously untreated patients with multiple myeloma: a phase I-II trial.

Cooper MR, Fefer A, Thompson J, Case DC Jr, Kempf R, Sacher R, Neefe J, Bickers J, Scarffe JH, Spiegel RJ, et al.

Invest New Drugs. 1987;5 Suppl:S41-6.PMID: 3597002 [PubMed - indexed for MEDLINE]Related articles

Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden.

Osterborg A, Björkholm M, Björeman M, Brenning G, Carlson K, Celsing F, Gahrton G, Grimfors G, Gyllenhammar H, Hast R, et al.

Blood. 1993 Mar 15;81(6):1428-34.PMID: 8453092 [PubMed - indexed for MEDLINE]Related articlesFree article

Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.

Hulin C, Facon T, Rodon P, Pegourie B, Benboubker L, Doyen C, Dib M, Guillerm G, Salles B, Eschard JP, Lenain P, Casassus P, Azaïs I, Decaux O, Garderet L, Mathiot C, Fontan J, Lafon I, Virion JM, Moreau P.

J Clin Oncol. 2009 Aug 1;27(22):3664-70. Epub 2009 May 18.PMID: 19451428 [PubMed - indexed for MEDLINE]Related articles

Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.

Cavo M, Benni M, Ronconi S, Fiacchini M, Gozzetti A, Zamagni E, Cellini C, Tosi P, Baccarani M, Tura S; Writing Committee of the "Bologna 90" Clinical Trial.

Haematologica. 2002 Sep;87(9):934-42.PMID: 12217805 [PubMed - indexed for MEDLINE]Related articlesFree article